

L52: Entry 8 of 9

File: DWPI

Apr 6, 1989

DERWENT-ACC-NO: 1989-114242

DERWENT-WEEK: 198915

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Treatment of hypertension and other diseases - by chronic admin. of tryptophan or 5-hydroxy-tryptophan

INVENTOR: CADE, J R; FREGLY, M J

PATENT-ASSIGNEE:

ASSIGNEE	CODE
UNIV FLORIDA	UYFL
CADE J RRIDA	CADEI
FREGLY M JDA	FREGI

PRIORITY-DATA: 1987US-0102723 (September 30, 1987)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 8902737 A	April 6, 1989	E	084	
CA 1328079 C	March 29, 1994		000	A61K031/405
DE 3888827 G	May 5, 1994		000	A61K031/405
EP 342211 A	November 23, 1989	E	000	
EP 342211 B1	March 30, 1994	E	004	A61K031/405

DESIGNATED-STATES: DK FI JP NO US AT BE CH DE FR GB IT LU NL SE AT BE CH DE FR GB IT LI LU NL SE AT BE CH DE FR GB IT LI LU NL SE

CITED-DOCUMENTS: 4.Jnl.Ref; US 4296119 ; US 4329356 ; WO 8503873 ; 1.Jnl.Ref

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
WO 8902737A	September 28, 1988	1988WO-US03302	
CA 1328079C	September 30, 1988	1988CA-0579054	
DE 3888827G	September 28, 1988	1988DE-3888827	
DE 3888827G	September 28, 1988	1988EP-0909260	
DE 3888827G	September 28, 1988	1988WO-US03302	
DE 3888827G		EP 342211	Based on
DE 3888827G		WO 8902737	Based on
EP 342211A	September 28, 1988	1988EP-0909260	
EP 342211B1	September 28, 1988	1988EP-0909260	
EP 342211B1	September 28, 1988	1988WO-US03302	
EP 342211B1		WO 8902737	Based on

INT-CL (IPC): A23K 1/16; A23L 1/30; A61K 31/40; A61K 31/405

ABSTRACTED-PUB-NO: EP 342211B

BASIC-ABSTRACT:

Treatment of hypertension, cardiac or renal hypertrophy, polydipsia, polyurea, stroke or atherosclerosis in humans or animals is effected by chromic admin. of L-tryptophan, L-5-hydroxytryptophan and/or their salts at a daily dose of 4-10g.

More specifically, the daily dose is 4-6g, esp. administered as a dietary supplement.

In an example, unilaterally nephrectomised rats were implanted with tubes contg. deoxycorticosterone acetate and given a feed contg. (a) no additive, (b) 2.5% tryptophan or (c) 5% tryptophan. After 5 weeks, urine output was (a) 268.2, (b) 241.4, (c) 164.6 ml/kg; urinary Na output was (a) 55.5, (b) 51.9, (c) 34.2 meq/kg; urinary K output was (a) 13.3, (b) 13.4, (c) 12.2 meq/kg; and urinary creatinine output was (a) 38.5, (b) 40.5, (c) 37.9 mg/kg.

ABSTRACTED-PUB-NO:

WO 8902737A

EQUIVALENT-ABSTRACTS:

Use of L-tryptophan and/or L-5-hydroxytryptophan and/or a pharmaceutically acceptable salt thereof as active ingredient(s) in the manufacture of a medicament for the treatment of atherosclerosis in a human or non-human animal.

CHOSEN-DRAWING: Dwg.0/22

TITLE-TERMS: TREAT HYPERTENSIVE DISEASE CHRONIC ADMINISTER TRYPTOPHAN HYDROXY TRYPTOPHAN

DERWENT-CLASS: B02 C02

CPI-CODES: B06-D01; B12-F01B; B12-F05; B12-G03; B12-H03; C06-D01; C12-F01B; C12-F05; C12-G03; C12-H03;

CHEMICAL-CODES:

Chemical Indexing M2 *01*

Fragmentation Code

D011 D601 H1 H100 H181 J0 J011 J1 J171 M280
 M312 M321 M332 M343 M349 M371 M391 M412 M511 M520
 M530 M540 M630 M640 M650 M781 M903 M904 M910 P523
 P526 P723 P814
 Specfic Compounds
 03943U 15668U
 Registry Numbers
 1704X 1724X 1711X 1714X

Chemical Indexing M2 *02*

Fragmentation Code

D011 D022 D601 H1 H100 H181 H4 H401 H441 H8
 J0 J011 J1 J171 M280 M312 M321 M332 M343 M349
 M371 M391 M412 M511 M520 M530 M540 M630 M640 M650
 M781 M903 M904 M910 P523 P526 P723 P814
 Specfic Compounds
 17528U 17529U
 Registry Numbers
 1704X 1724X 1711X 1714X

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0080U; 0110U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1989-050562